Four IPOs and a SPAC pitch a new slate of microbiome, cancer and inflammatory drugs to Wall Street
Biotech IPOs are still coming in all sorts of flavors these days.
Just look at what’s on the menu from Friday: There’s Finch Therapeutics, which …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
